Plaque

VENTYX BIOSCIENCES, INC. (NASDAQ: VTYX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ventyx Biosciences, Inc.

Retrieved on: 
Monday, March 18, 2024
Psoriasis, District court, Defendant, News, IPO, Inflammation, Plaque, Complaint, Action Replay, Court, Advertising, Security (finance)

Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .

Key Points: 
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 30, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTYX

Retrieved on: 
Friday, March 15, 2024
Psoriasis, Register, Form, District court, Defendant, News, Ext, LLP, IPO, Security (finance), Inflammation, Plaque, Prospectus, Complaint, File, Pomerantz, Action Replay, Court, Person

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.

Key Points: 
  • NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Benevis Report Emphasizes the Need to Prioritize Adolescent Dental Health in Honor of World Oral Health Day

Retrieved on: 
Thursday, March 14, 2024
Research, Health, Dental care, Dentistry, Herbal cigarette, Growth, Caregiver, White, Risk, Education, Patient, Adolescence, History, Tooth decay, Children's Health Insurance Program, World Oral Health Day, Impact, Plaque, SDOH, Smoking, Crowding, Ortho, Jaw, Parent, Brace

"Access to quality dental care should be easy, especially when it's essential; however, millions of adolescents face barriers to treatment or lack of dental hygiene resources and education for healthy smiles," said Bryan Carey, CEO of Benevis. "As adolescents move closer to adulthood or further away from the support of their parents' dental insurance coverage, establishing strong oral health habits that they can maintain over a lifetime becomes even more important. This work begins in the household and within their dental home--the ongoing relationship with a dental provider--to prevent the early onset of dental disease and teach healthy behaviors." 

Key Points: 
  • Many oral diseases and harmful health behaviors managed by adults begin in adolescence.
  • Harmful behaviors with implications for adverse oral health outcomes, like dietary habits, smoking, vaping, and substance use, also become more common in adolescent years.
  • In the U.S., social determinants of health (SDOH) have risk factors that are directly linked to poor oral health outcomes and are attributed to social, economic, and geographic barriers.
  • Expanding access to equitable oral healthcare to support dental disparities during this vital stage of life is essential to adolescent health and well-being.

VTYX STOCKHOLDER NEWS: Contact Robbins LLP for Information Regarding the Ventyx Biosciences, Inc. Class Action

Retrieved on: 
Thursday, March 14, 2024
Psoriasis, SAN, News, LLP, IPO, Inflammation, Plaque, Pharmaceutical industry

Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.

Key Points: 
  • Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.
  • In 2022, Ventyx initiated a Phase 2 clinical trial of VTX958 for the treatment of moderate to severe plaque psoriasis (the “Phase 2 SERENITY Trial”).
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • In addition, during the class period, defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

PetIQ, Inc. Celebrates Expansion of Minties® Dental Treats Brand With Launch of New Dental Chew for Large-Sized Dogs

Retrieved on: 
Thursday, March 14, 2024
Plaque, Cat, Dog, Family, Parent, Dentistry

Recommended for dogs over fifty pounds, the Minties® large dental treat includes the tasty, breath-freshening ingredients found in Minties’® other best-selling dental treats for tiny/small (5 to 24 lbs) and medium-sized (25 to 50 lbs) dogs.

Key Points: 
  • Recommended for dogs over fifty pounds, the Minties® large dental treat includes the tasty, breath-freshening ingredients found in Minties’® other best-selling dental treats for tiny/small (5 to 24 lbs) and medium-sized (25 to 50 lbs) dogs.
  • With five natural breath fresheners – alfalfa, peppermint, parsley, fennel and dill – Minties® dental treats combat bad breath at the source.
  • Tiny/Small- and medium-sized dog Minties dental treats are also available online and in retail stores, alongside Minties® salmon- and chicken-flavored treats for cats.
  • For more information about Minties® dental treats, including where to purchase, visit Minties.com .

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

Retrieved on: 
Tuesday, March 12, 2024
Consensus, Moyamoya disease, Cardiovascular disease, Myocardial infarction, Dyslipidemia, CVD, Cardiology, Risk, Patient, Apolipoprotein B, Consensus decision-making, Stroke, NAMS, ASCVD, Plaque, Artery, Diet, Cleveland Clinic, Ezetimibe, Clinical trial, Safety, FDC, Apolipoprotein, Genetic disorder, Physician, Pharmaceutical industry

NAARDEN, The Netherlands and MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the dosing of the first patient and initiation of TANDEM, a pivotal Phase 3 clinical trial to evaluate obicetrapib and ezetimibe FDC in adult patients with Heterozygous Familial Hypercholesterolemia (“HeFH”) and/or Atherosclerotic Cardiovascular Disease (“ASCVD”) or multiple risk factors for ASCVD, whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-modifying therapies.

Key Points: 
  • The ACC Expert Consensus set LDL-C goals of below the 70mg/dl for patients with ASCVD and below the 55mg/dl goal for ASCVD patients with very high risk.
  • The primary objective of the placebo-controlled, double-blind, four-arm, randomized TANDEM trial is to evaluate the effect of 10mg obicetrapib and 10mg ezetimibe FDC on LDL-C levels, compared to both ezetimibe 10mg and obicetrapib 10mg monotherapy and to placebo.
  • NewAmsterdam anticipates enrolling approximately 400 patients on maximally tolerated lipid-modifying therapies with HeFH, ASCVD or ASCVD risk equivalents and who have a baseline LDL-C of at least 70 mg/Dl.
  • Patients who have multiple risk factors for ASCVD are at high risk of experiencing a cardiovascular event in the near future.

VTYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ventyx Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, March 12, 2024
Psoriasis, Defendant, News, IPO, Inflammation, Plaque, Prospectus, Complaint, Court, Person, Pharmaceutical industry

Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.

Key Points: 
  • Ventyx is a clinical-stage biopharmaceutical company that develops small molecule product candidates to address a range of inflammatory diseases.
  • The Company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

TheraBreath™ Brand Expands Product Line with Deep Clean and Overnight Oral Rinses

Retrieved on: 
Friday, April 5, 2024
Women, Discount, Variety, Department Stores, Men, Other Retail, Family, Supermarket, Specialty, Other Health, Consumer, Cosmetics, Retail, Teens, Children, Baby, Maternity, Dental, LGBTQ+, Convenience Store, Home Goods, Health, Plaque, Dentistry, Oral hygiene, Walmart, Research, Gingivitis

TheraBreath™ brand, the fastest-growing mouthwash brand in the U.S. among leading brands, announces two new additions to the oral care aisle: TheraBreath Deep Clean Oral Rinse and TheraBreath Overnight Oral Rinse .

Key Points: 
  • TheraBreath™ brand, the fastest-growing mouthwash brand in the U.S. among leading brands, announces two new additions to the oral care aisle: TheraBreath Deep Clean Oral Rinse and TheraBreath Overnight Oral Rinse .
  • TheraBreath Deep Clean Oral Rinse marks the brand’s debut with antiseptic benefits all while preserving their signature alcohol-free formula across their oral rinses.
  • Specially intended for nighttime use, TheraBreath Overnight Oral Rinse is an anticavity fluoride rinse that fights bad breath for 12 hours**.
  • TheraBreath Deep Clean Oral Rinse and TheraBreath Overnight Oral Rinse are now available at retailers nationwide such as Walmart , Walgreens , and Target in addition to Amazon .

Frontdoor Announces 2024 National Contractor Award Winners

Retrieved on: 
Thursday, April 4, 2024
Residential Building & Real Estate, Commercial Building & Real Estate, Manufacturing, Construction & Property, Professional Services, Landscape, Building Systems, Architecture, HVAC, Insurance, Other Construction & Property, Lite, AHS, Service, Plaque, American Home, Multimedia, American Home Shield, Prosper, Heat

Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading provider of home service warranties and parent company of American Home Shield, today announced the winners of the American Home Shield 2024 Pinnacle Award for Service Excellence.

Key Points: 
  • Frontdoor, Inc. (NASDAQ: FTDR), the nation’s leading provider of home service warranties and parent company of American Home Shield, today announced the winners of the American Home Shield 2024 Pinnacle Award for Service Excellence.
  • All are preferred contractors, a designation Frontdoor places on the highest quality contractors.
  • Each recipient received a check for $25,000, an engraved plaque and certificate recognizing their achievement, and a truck magnet.
  • To learn more about becoming a contractor for American Home Shield or Frontdoor, please visit https://www.frontdoor.com/pro/join .

Dr. Reymond Clavel and Marc-Olivier Demaurex, Pioneers of the Delta Robot, and Robotics Leader Joe Gemma Selected for 2024 Joseph F. Engelberger Robotics Awards

Retrieved on: 
Thursday, April 4, 2024
Technology, Mobile, Wireless, Packaging, Engineering, Robotics, Automotive Manufacturing, Aerospace, Manufacturing, Machinery, Transport, Hardware, Other Manufacturing, Logistics, Supply Chain Management, Textiles, Joseph, University, Hermes, Artificial intelligence, Automation, Original equipment manufacturer, KUKA, Education, RIA, Corner, Organization, Research, Gemma, Robotic Industries Association, Family, Conference, Growth, EPFL, Wauseon, Ohio, Doctor of Philosophy, Plaque, École polytechnique, Japan Robot Association

The Association for Advancing Automation (A3) announced three longtime industry pioneers as the winners of the 2024 Joseph F. Engelberger Robotics Awards, the world's most prestigious robotics honor.

Key Points: 
  • The Association for Advancing Automation (A3) announced three longtime industry pioneers as the winners of the 2024 Joseph F. Engelberger Robotics Awards, the world's most prestigious robotics honor.
  • Marc-Olivier Demaurex, was selected as a technology winner for his role in pioneering the Delta robot and bringing it to market.
  • The Joseph F. Engelberger Robotics Awards are named after the late Joseph F. Engelberger, known throughout the world as the founding force behind industrial robotics.
  • “The honorees of this year’s Joseph F. Engelberger Robotics Awards have all played critical roles in the development and growth of our industry,” said Jeff Burnstein, president of A3.